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MedIcare hePatItIs c PatIents – are PatIents under 65 dIfferent?
Meckley L.M., Wang Z., Miyasato G., Scaife J., Sanchez H.
Trinity Partners, LLC, Waltham, MA, USA
Objectives: Previous studies have shown that the majority of Medicare patients 
with HCV are under age 65. This study examines how patient characteristics and 
cost differ between Medicare patient age groups. MethOds: An analysis of HCV 
patients was conducted using the 2010-2011 Centers for Medicare and Medicaid 
Services Parts A and B fee-for-service claims. Patients with an HCV ICD-9 code 
and 6 months of follow-up were included. Patient characteristics, resource utili-
zation and 6-month costs were compared between patients age< 65 and age≥ 65. 
The impact of age on medical costs adjusting for demographics, reason for 
entitlement(OREC), Medicaid status, and overall health status (measured by CCI) 
was assessed using generalized linear models fit with a gamma distribution and log 
link function. Results: 16,417 HCV patients with complete data were identified. 
Patients under 65 (n= 11,286) were more likely to have an OREC of disability (89%), 
while patients 65+ OREC was primarily due to old age and survivors insurance (80%). 
ESRD accounted for 8.8% of patients age< 65 and 1.7% aged 65+. Medicaid dual-
eligibility was twice as common among younger patients (38.0% vs. 66.8%, p< 0.01). 
Younger patients had a higher prevalence of alcoholism (35.6% vs. 30.6%, p< 0.01) 
and drug abuse (43.3% vs. 12.2%, p< 0.01), comorbidities that are also risk factors for 
HCV. Yet overall health, as measured by CCI, was higher for younger patients (1.82 
vs. 2.51, p< 0.01). Younger patients had more hospitalizations (0.48 vs 0.33, p< 0.01) 
and emergency department visits (2.04 vs. 1.77, p< 0.01). 6-month medical costs 
for patients age< 65 were $1,285 higher than those 65+ (p= 0.01). After adjusting 
for OREC, HCV-related comorbidities, CCI, demographics and Medicaid status, age 
was no longer associated with cost. cOnclusiOns: Medicare HCV patients under 
65 are more expensive to treat. However, this appears to be due to higher rates of 
disability, ESRD and comorbidities, rather than age itself.
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Objectives: To study cost of illness (COI) by calculating direct and indirect cost 
in the patients with gastrointestinal and liver disease from societal perspec-
tive. MethOds: Study was conducted in general medicine ward of government 
tertiary care hospital, north India by including inpatients diagnosed with gastro-
intestinal and liver disorders. In terms of time perspective prevalence approach 
was used to study COI. Direct cost was estimated using admission fee, cost of bed, 
diet charge, cost of medications and diagnostic tests/surgical procedures. Indirect 
cost was estimated using loss of wages, travelling cost, food cost, and cost of bed 
for attendant/s of patient due to hospital stay. Estimated costs were converted to 
purchasing power parity dolor (PPP$) for cross country comparison. To estimate the 
productivity loss, human capital approach was used with assumption that income 
reflects productivity. Results: A total 202 patients (83% males) were included in 
the study. Most prevalent disorder includes alcoholic liver disease (32.5%) and most 
common class of drug prescribed was proton pump inhibitor (94%). Majority of the 
patients (53%) with these diseases has hospital stay of 1 to 7 days. The total direct 
costs and indirect cost of disease for study patients were PPP$ 23518 and PPP$ 30187 
respectively. Direct and indirect cost of disease for each patient was PPP$ 231 and 
PPP$ 277 respectively. The cost of medication (17.8%) and loss of wages (43.9%) 
contributes major component of direct and indirect cost respectively. Total cost for 
males (PPP$ 276.0±145) is significantly higher (P < 0.05) than the total cost for females 
(PPP$ 232.6±146.6). Mean direct and indirect costs incurred by female patients were 
significant less than that of male patients. cOnclusiOns: Cost of medication and 
loss of wages of patients contributes major component of COI. Increasing the num-
ber of day of hospital stay leads to higher cost of burden.
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Objectives: The aim of the study is to estimate the cost of Hepatitis C in Turkey 
through reaching consensus on the current clinical practice, resource use and 
the course of treatment. MethOds: This study uses the Delphi method to reach 
experts’ consensus on the clinical practices currently being used in Turkey. Delphi 
method has been widely used in medical areas where empirical data is scarce. 
The survey developed for this study includes questions to understand the clinical 
resource use in order to calculate the associated costs. According to the literature, 
the panelists’ answers are unlikely to change after the second iteration. Similar 
to theory, a two-iteration panel was needed to reach a consensus in practice. The 
consensus is then used to calculate the cost of chronic hepatitis C, compensated 
cirrhosis, decompensated cirrhosis, hepatocarcinoma and liver transplant health 
states from the payer’s perspective. Results: The Delphi panel included gastroen-
terologists, infectious diseases specialists and a gastroenterologist with transplan-
tation experience. According to panel consensus, among all of the patients that an 
expert follows, the rate of patients who need hepatitis C treatment (regardless of 
diagnosis) is 1% for gastroenterologists and 20% for infectious diseases specialists. 
ended and open ended multi-country questionnaire was designed to collect data 
from 715 participants (186 Barbers and 529 Clients). Blood samples were withdrawn 
after obtaining an informed consent and were tested for HBV and HCV markers 
by Chromatography, enzyme-lined immunosorbent assay (ELISA) and polymerase 
chain reaction (PCR). Results: The mean age was 28.47±9.7 years in both groups 
of Barbers (n-186) and Clients (n= 529). Among both groups, the sero-prevalence 
of HBV and HCV was 5.7% and 14.4%, respectively. Clients knew about hepatitis 
B and C viruses while barbers were not quite aware. The knowledge about the 
route of transmission was poor among barbers and good among clients. Half of 
the respondents in both groups knew about hepatitis B vaccination and only 15% 
were vaccinated. Sixty percent of the barbers claimed disinfecting the instruments 
between clients and (88.9%) claimed using of new blades. During actual obser-
vation of practices, only 28% disinfected instruments between clients and 62% 
used new blades for each client. cOnclusiOns: There is some awareness among 
barbers and clients about hepatitis B and C viruses but poor knowledge about the 
mode of transmission. This warrants conducting health education campaigns 
to increase awareness about these two blood borne viruses and the risk factors 
associated with their transmission particularly at barbers’ shop and to implement 
interventions to prevent spreading Hepatitis.
GastroIntestInal dIsorders – cost studies
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Objectives: Reduction in operative time has been shown to offer significant 
clinical benefits in many procedures including hernia repair surgeries. Ethicon 
Securestrap™ Open, a new mechanical absorbable strap fixation device, takes 
significantly shorter time compared to hand-sutured fixation of IPOM mesh in 
open ventral hernia surgery. This analysis assesses the potential economic value 
of reduction in operative time with mechanical fixation compared to suture fixa-
tion. MethOds: An economic model was developed to evaluate the budget impact 
to hospitals of adopting Ethicon Securestrap™ Open repair of ventral hernia. A 
reduction in mean fixation time comparing suture to mechanical fixation was 
included based on a preclinical study that demonstrated about 89% reduction. 
Related benefits in terms of risk of surgical site infections, owing to shorter oper-
ative duration were included based on the literature. Costs of the mechanical 
fixation device and suture supplies, OR time, anesthesia time, and potentially 
avoided surgical site infections were considered in the economic model. Results: 
Based on the model inputs, an overall potential saving of $259,604 (43%) was 
estimated for 100 fixations if they were done using Ethicon Securestrap™ Open 
versus sutures. Although the use of Ethicon Securestrap™ Open added $50,000 in 
supplies costs, this was completely offset by potential savings in OR time costs 
($186,570), potential reduction in avoided surgical site infection or seroma costs 
due to shorter operating room time ($104,210), and in anesthesia costs ($14,324). 
Use of Ethicon Securestrap™ Open was also estimated to be potentially freeing 
up a total of about 58 hours in OR time per 100 conversions. cOnclusiOns: This 
analysis represents the first economic evaluation of Ethicon Securestrap™ Open 
use in open ventral hernia surgery. Adoption of Ethicon Securestrap™ Open fixa-
tion device would likely result in significant savings for hospitals, driven by shorter 
procedure time and its related clinical benefits.
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Objectives: Hemostasis after liver resection may be difficult to achieve and there 
is thus an increased focus on reducing blood loss and resource use with hemo-
static products. This study estimated the cost impact of a novel fibrin sealant 
patch (i.e., EVARREST) vs. standard of care (SoC) for bleeding control in hepatic 
resection. MethOds: An economic analysis quantified 30-day cost impact of 
EVARREST vs. SoC from a German hospital perspective. This analysis used data 
from a randomized trial, which included aggregated resource use reported within 
30 days. Resources included initial treatment and re-treatment, operating time, 
hospitalization, transfusions, and ventilator. SoC was composed of manual com-
pression with a small percentage using hemostats. The primary analysis included 
resources clinically related to the significant hemostasis benefit of EVARREST vs. 
SoC (i.e., initial treatment and re-treatment with hemostasis methods, operating 
time, transfusions, and blood units). A secondary analysis included all resources 
evaluated in the primary analysis with the addition of hospital stay, proportion of 
patients using ventilator, and mean ventilator hours. A projected global price for 
EVARREST was used based on average USD to Euro exchange rate over the last 10 
years. Published data on German costs were applied to resource use. Sensitivity 
analyses were conducted on several variables including EVARREST costs (€ 472 to 
€ 735) for available sizes. Results: The primary analysis predicted that EVARREST 
acquisition cost is offset with cost impact reduced to € 82 per patient vs. SoC (sensi-
tivity range: -€ 86 to € 225). Secondary analyses predicted further resource reduction 
with EVARREST leading to cost-savings (i.e., -€ 458 per patient). Operating time and 
hospital stay were important analysis drivers. cOnclusiOns: This analysis sug-
gests that EVARREST may result in cost savings, in addition to meeting an impor-
tant unmet need for controlling bleeding in hepatic surgery. Further study in more 
patients may be required to confirm findings.
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total cost, quality-adjusted life years (QALYs), cumulative incidence of cirrhosis, 
decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related 
deaths (LRD). We also projected the number of new HCV infections in society due to 
HCV-infected people released from prisons. Results: The total costs under no and 
5YR screening were $6.9 million and $8.3 million per 10,000 people, respectively for 
30-year simulation. The corresponding QALYs were 190,428 and 190,462, respectively. 
The incremental cost-effectiveness ratio of 5YR screening was $43,000 per QALY. In 
comparison with no screening, 5YR screening can avoid 136,000 new HCV infections 
in the next 30 years, where 71% of these infections can be attributed to infected per-
sons released from prisons back in the society. The 5-year screening can also reduce 
the cumulative incidence of DC, HCC, LT and LRD by 14-17%. cOnclusiOns: HCV 
screening followed by treatment in prisons is cost-effective at $50,000 willingness-
to-pay. Resources spent in prisons can substantially reduce the burden of HCV in 
both prisons and the society at large.
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Objectives: The optimal management of patients with suspected biliary obstruc-
tion remains unclear, and includes the possible performance of magnetic resonance 
cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancrea-
tography (ERCP). We completed a medical effectiveness randomized trial comparing 
an ERCP-first to a MRCP-first approach in patients with suspected bile duct obstruc-
tion. MethOds: The management strategies are based on a medical effectiveness 
trial of 257 patients over a 10-month follow-up period. Direct and indirect costs were 
included, adopting a societal perspective. The cost values are expressed in 2012 
Canadian dollars. Results: Direct costs attributable to visits were CAN$5350 in the 
ERCP and CAN$5750 in the MRCP group. The procedures costs were CAN$233,852 
and CAN$267,952 for the ERCP and MRCP groups, respectively. Second procedures 
were incurred twice more in the MRCP than in the ERCP group. Direct costs of com-
plications amounted to CAN$207,708 (ERCP group) and CAN$252,347 (MRCP group). 
Total direct costs added up to CAN$446,910 for the 126 patients in the ERCP-first 
strategy and CAN$525,689 for the 131 MRCP-first patients. With regards to indirect 
costs, MRCP group patients spent more days in scheduled GI visits (8 days) and 
hospitalizations (49 days), but less days in procedures (18 days) and in time away 
from activity of daily living (44 days). Overall total indirect costs were quite similar 
(ERCP-first CAN$92,219 versus MRCP-first CAN$90,912). cOnclusiOns: This cost 
analysis suggests only a small difference in total costs, favoring the ERCP-first group, 
and is principally attributable to procedures and hospitalizations with little impact 
from indirect cost measurements.
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Objectives: A decision-analytic Markov model was developed to predict the 
health outcomes of using sofosbuvir (SOF) -based regimen compared with cur-
rent treatment options for patients who are co-infected with hepatitis C (HCV) 
and HIV. MethOds: The analysis modeled a cohort of treatment-naïve genotype 1 
patients co-infected with HIV and HCV with a mean age of 54 years and 25% with 
cirrhosis. The model was evaluated from a US third-party payer perspective for a 
lifetime time horizon. SOF+pegylated interferon + ribavirin (PR) for 12 weeks was 
compared with telaprevir (TVR)+PR for 48 weeks, and boceprevir (BOC)+PR for 48 
weeks. Sustained virologic response (SVR) rates were derived from clinical trials 
conducted in the HCV/HIV co-infected patient population. Transition probability, 
utility, and cost estimates were based on a literature review, public sources, and 
consensus by a panel of 4 hepatologists. Results: In the HCV/HIV co-infected 
cohort, the SOF-based regimen was associated with the lowest incidence of liver dis-
ease complications including hepatocellular carcinoma, decompensated cirrhosis, 
need for liver transplantation, and HCV-related death (reduction of 52% compared 
to TVR+PR and 65% compared to BOC+PR). In addition, patients receiving SOF+PR 
experienced more quality-adjusted life-years (QALYs), compared to those treated 
with other options (ranged from 0.63 to 1.10 QALYs). In terms of incremental qual-
ity adjusted life years gained, SOF+PR dominated over TVR+PR and BOC+PR. The 
sensitivity analysis indicated that the results were robust to changes in model 
inputs and assumptions, such as SVR rates, adverse event incidence, costs for treat-
ment monitoring and management of adverse events, and transition probability 
estimates. cOnclusiOns: The SOF-based regimen of shorter duration, improved 
tolerability profile and high SVR rates was projected to yield the most favorable 
health and economic outcomes in the genotype 1 HIV and HCV co-infected popula-
tion compared to current treatment regimens using telaprevir or boceprevir.
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econoMIc evaluatIons of treatMents for InflaMMatory bowel 
dIseases
Lachaine J., Miron A., Beauchemin C.
University of Montreal, Montreal, QC, Canada
Objectives: In recent years, there has been a rapid growth in the development of 
novel biological treatments. Numerous economic evaluations have been performed 
to evaluate these treatments in inflammatory bowel diseases (IBD). The objective 
of this project was to explore the existing evidences regarding the cost-effective-
ness of treatments in IBD. MethOds: A systematic review of the literature was 
50% of Hepatitis C patients in Turkey are female and the mean age of patients is 50. 
Approximately 60% of patients are treatment naïve. Approximately 900 liver trans-
plants are performed in Turkey per year and the success rate is around 85%. From 
the payer’s perspective, the average annual cost (excluding hepatitis C drug costs) 
of a chronic hepatitis C, compensated cirrhosis, decompensated cirrhosis, hepato-
carcinoma and liver transplant patient is USD 446.83, USD 577.56, USD 1984.39, USD 
2474.15, USD 42,469.27 respectively. cOnclusiOns: Early diagnosis and treatment 
is crucial not only from the clinical perspective, but also from the cost perspective 
as a more severe disease costs significantly more.
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Objectives: New all oral HCV therapies are recognized as having higher cure rates 
than current standard of care (SOC) treatments. However, the cost-benefit of providing 
new all oral therapy versus SOC treatment is currently unknown. We undertook a 
study to examine the financial impact of anticipated all oral therapy for genotype 
1 disease and approved all oral therapy for genotypes 2 and 3 disease versus SOC 
treatments. MethOds: We calculated pharmacy costs of approved drugs using 
wholesale acquisition costs, assuming a full course of therapy for genotypes 1, 2, 
and 3 diseases, respectively. Anticipated all oral therapy for genotype 1 was esti-
mated at 1.5 times the cost of all oral therapy for genotype 2. Costs for medical 
treatment over 14 years were based on published data for four therapeutic end-
points: cured, not cured and no cirrhosis, not cured with cirrhosis, not cured with 
cirrhosis and end stage liver disease. The study also accounted for the frequency 
of genotypes 1, 2, and 3 HCV disease within the U.S. population for pooled analysis 
across genotypes. Results: Genotype 1 all oral therapy is anticipated to provide 
overall cost savings of 13% compared to SOC. However, overall costs among approved 
genotypes 2 and 3 all oral therapy were 9% and 44% higher compared to SOC even 
with cure rates 20% and 18% higher. After accounting for genotype frequency 
within the general U.S. population, pooled analysis across genotypes showed a net 
cost savings of $1,248 per utilizing member per year for all oral treatment versus 
SOC. cOnclusiOns: If our predicted cost of new genotype 1 therapy is accurate, 
cost savings will only be observed among the anticipated new all oral therapy for 
genotype 1 disease. However, these savings will provide a net cost savings across 
genotypes for all oral therapy compared to SOC treatment.
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Objectives: To evaluate the cost-effectiveness of adalimumab plus standard of 
care (ADA+SOC) vs. SOC alone in moderate-to-severe ulcerative colitis (UC) patients 
with an inadequate response to SOC and to assess the total cost differences compar-
ing ADA+SOC to infliximab (IFX)+SOC and to golimumab (GOL)+SOC. MethOds: 
A Markov model was developed to simulate the progression of patients receiv-
ing ADA+SOC or SOC over a 5-year time horizon from the Canadian publicly-
funded health system’s perspective, considering direct costs only in the base case. 
Transitional probabilities of pre-surgery and surgery-related states for ADA+SOC 
and SOC were derived from ADA trials and from literature. Health utility and cost 
inputs (medications, medical services, surgery, and surgery-related mortality) came 
mainly from literature. Additionally, a cost-minimization analysis (CMA) compared 
the total 5-year costs of biologics (ADA, IFX and GOL) assuming IFX and GOL having 
the same efficacy as ADA. Results were expressed in costs per quality-adjusted-life-
years (QALY) gained for ADA+SOC vs. SOC alone and in total cost differences for 
ADA+SOC vs. IFX+SOC and vs. GOL+SOC. Deterministic and probabilistic sensitivity 
analyses (DSA, PSA) were performed. Results: In the base case, the incremen-
tal costs per QALY gained for ADA+SOC vs. SOC were C$96,812 (in 2013 Canadian 
dollars [C$]). Results from DSA ranged from C$62,362 to C$109,461. PSA revealed 
that ADA+SOC was cost-effective in 58% and 81% of cases at C$100,000/QALY and 
C$120,000/QALY thresholds, respectively. The CMA predicted total cost savings of 
C$23,823 and C$4,279 comparing ADA+SOC to IFX+SOC and to GOL+SOC over 5 
years. DSA and PSA results showed that ADA+SOC led to cost savings in all scenarios 
comparing to IFX+SOC and in all but one DSA-based and all PSA-based scenarios 
comparing to GOL+SOC. cOnclusiOns: The ADA+SOC strategy appeared to pro-
vide reasonable cost-effectiveness value compared with SOC alone and significant 
cost-saving benefits compared to IFX+SOC and GOL+SOC.
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Objectives: The seroprevalence of hepatitis C virus (HCV) is 16-41% in United 
States (US) prisons, yet no standard protocols exist for HCV screening. The objective 
of our study was to evaluate the cost-effectiveness HCV screening in prisons and 
HCV prevention in society by interventions in prisons MethOds: We developed 
an agent-based simulation model that simulated the transmission and progres-
sion of HCV disease in US population in prisons and society. Injection drug use 
was the main route of HCV transmission. Chronic stages of HCV were modeled 
as Markov states. We used US Department of Justice data to simulate movement 
of people between prisons and society. We evaluated two screening scenarios: no 
screening, and 1-time screening of all existing inmates followed by screening (and 
treatment) of any incoming inmate for 5 years (5YR screening). We projected the 
